Illustration of the Management and Prognosis of Japanese Patients with Cardiac Sarcoidosis

Conditions

Cardiac Sarcoidosis

Takatsugu Segawa, Tatsunori Taniguchi, Takeru Nabeta, Yoshihisa Naruse, Takeshi Kitai et al. (11 authors)

European Heart Journal Open2024-12-241 citations

10.1093/ehjopen/oeae100

Sex differences in clinical characteristics and prognosis of patients with cardiac sarcoidosis

Takashi Iso, Daichi Maeda, Yuya Matsue, Taishi Dotare, Tsutomu Sunayama et al. (14 authors)

Heart2023-04-2521 citations

10.1136/heartjnl-2022-322243

The Prognostic Value of B‐Type Natriuretic Peptide in Patients With Cardiac Sarcoidosis Without Heart Failure: Insights From ILLUMINATE‐CS

Shota Miyakuni, Daichi Maeda, Yuya Matsue, Kenji Yoshioka, Taishi Dotare et al. (15 authors)

Journal of the American Heart Association2022-12-1412 citations

10.1161/jaha.122.025803

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with cardiac sarcoidosis from January 1st, 2001 to December 31st, 2017. Diagnosis of CS is according to either Japanese Circulation Society (JCS) criteria proposed in 2016 or the Heart Rhythm Society (HRS) 2014 consensus statement

Exclusion criteria

Exclusion criteria: The exclusion criterion was the refusal of a patient to be enrolled after notification that he/she is registered to this registry

Design outcomes

Primary

Measure	Time frame
Composite cardiac events after diagnosed cardiac sarcoidosis. Cardiac events include HF admission, documented VT/VF, and death.	—

Secondary

Measure	Time frame
1. Change in cardiac function after steroid therapy 2. Resolution of atrioventricular block after steroid therapy 3. Change in inflammatory activity by imaging modality after steroid therapy 4. Efficacy of catheter ablation to ventricular tachycardia	—

Countries

Japan

Contacts

Public ContactTakeru Nabeta

Kitasato University School of Medicine Cardiovascular Medicine

nabetake@med.kitasato-u.ac.jp0427788111

Outcome results